Le Lézard
Classified in: Health
Subject: SVY

Global Atherosclerosis Partnering Report 2018: Access to Deals and Agreements by the World's Leading Healthcare Companies Since 2012



DUBLIN, March 8, 2018 /PRNewswire/ --

The "Global Atherosclerosis Partnering 2012 to 2018" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The Global Atherosclerosis Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Key Topics Covered:

Executive Summary

Chapter 1 - Therapy Partnering trends in numbers

Partnering in numbers - by year
Partnering in numbers - most active
Partnering in numbers - by industry sector
Partnering in numbers - by deal type
Partnering in numbers - by technology type
Partnering in numbers - by stage of development

Chapter 2 - Most active dealmakers

Chapter 3 - Partnering deals directory

Partnering deals directory - by company A-Z
Partnering deals directory - by deal value
Partnering deals directory - by industry sector
Partnering deals directory - by deal type
Partnering deals directory - by stage of development
Partnering deals directory - by technology area

Chapter 4 - Partnering deals with a contract document

Chapter 5 - M&A in numbers

M&A in numbers - by year

Chapter 6 - M&A deals directory

M&A deals directory - by company A-Z
M&A deals directory - by deal value

Chapter 7 - Financing in numbers

Financing in numbers - by year
Financing in numbers - by financing type

Chapter 8 - Financing deals directory

Financing deals directory - by company A-Z
Financing deals directory - by deal value
Financing deals directory - by financing type

For more information about this report visit https://www.researchandmarkets.com/research/4z83zm/global?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 02:00
LAKE ORION, Mich., June 23, 2018 /PRNewswire-PRWeb/ -- Women's Excellence's goal is treating the whole person. All of their services reflect the comprehensive nature of their philosophies of treatment. Evaluation or standard laboratory data is...

at 00:00
BIRMINGHAM, LAKE ORION, CLARKSTON, ROCHESTER and WEST BLOOMFIELD, Mich., June 23, 2018 /PRNewswire-PRWeb/ -- Many women are confused about their direction with respect to fertility once they have been diagnosed with endometriosis. These women need a...

22 jun 2018
PHOENIX, June 22, 2018 /PRNewswire-PRWeb/ -- Health Data Decisions' CEO Michael Blumental will partner with Janine Sala, Associate Director of Clinical Quality at UnitedHealthcare, to deliver the keynote for the HEDIS® track at the 3rd Annual RISE...

22 jun 2018
Cellenkostm and The University Of Texas Health Science Center at Houston today announce a research collaboration for application of cord blood-derived regulatory T cells (CK0801) as adoptive therapy for treatment of neuroinflammatory disorders. The...

22 jun 2018
DANVERS, Mass., June 22, 2018 /PRNewswire-PRWeb/ -- Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services announced that two of its antibody clones, ALK (D5F3®) and ROS1 (D4D6®), were featured in an article authored by...

22 jun 2018
The stunning announcement that CareSync, a Chronic Care Management company, has shuttered its doors has left their clients and patients without the services that helped manage a physician's sickest patients. Revenue Maximization Group (RMG)...




News published on 8 march 2018 at 15:30 and distributed by: